financetom
Business
financetom
/
Business
/
CES Energy Solutions Closes C$75 Million Reopening of Senior Unsecured Notes; Shares up 2%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CES Energy Solutions Closes C$75 Million Reopening of Senior Unsecured Notes; Shares up 2%
Oct 23, 2025 8:33 AM

11:26 AM EDT, 10/23/2025 (MT Newswires) -- CES Energy Solutions ( CESDF ) announced Thursday that it closed its previously announced private placement offering of an additional C$75 million aggregate principal amount of its 6.875% senior unsecured notes due May 24, 2029, representing an additional issuance to the $200 million aggregate principal amount of 6.875% senior unsecured notes issued on May 24, 2024.

A statement noted that, following the closing of the offering, there will be $275 million aggregate principal amount of initial notes and notes outstanding.

The company said that the notes were issued at a price of 103.125% of their face value, plus accrued interest from May 24, 2025, to, but excluding, the date of the closing of the offering, with a yield to worst of 5.559%.

The company also said that, other than issuance date, issuance price, and initial interest accrual date, the notes have "substantially identical terms" and are fungible, following the expiry of the applicable statutory hold period, with the initial notes and are issued as part of the same series.

CES Energy Solutions ( CESDF ) said that the net proceeds from the issuance of the notes will be used to repay outstanding indebtedness on the company's senior syndicated credit facility, and for general corporate purposes.

BMO Capital Markets and Scotiabank acted as joint active bookrunning managers for the private placement, in a syndicate.

"We are pleased to announce the successful closing of our $75 million senior unsecured notes offering, which was completed at an attractive price reflecting the strength of our business," said CES Energy Solutions' ( CESDF ) executive vice president and chief financial officer Anthony Aulicino. "The financing further improves our capital structure and provides ample liquidity to support potential future growth opportunities."

The company's shares were last seen up $0.21 to $9.40 on the Toronto Stock Exchange.

Price: 9.41, Change: +0.22, Percent Change: +2.39

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Decliners
Top Premarket Decliners
Jul 8, 2024
07:50 AM EDT, 07/08/2024 (MT Newswires) -- Beneficient (BENF) shares fell 15% Monday premarket after more than doubling on Friday. Koss Corporation ( KOSS ) shares were down 14%, shaving Friday's gains. Shineco ( SISI ) shares dropped 10%, reversing gains from the previous session. Price: 4.0800, Change: -0.76, Percent Change: -15.70 ...
AirBoss of America Begins Strategic Review
AirBoss of America Begins Strategic Review
Jul 8, 2024
07:50 AM EDT, 07/08/2024 (MT Newswires) -- AirBoss of America ( ABSSF ) said on Monday that it began a strategic review to explore alternatives for the company, including the potential monetization of its real estate assets. The company said the review is part of its transition plan to realign into two segments: AirBoss Rubber Solutions and AirBoss Manufactured Products....
iTeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment
iTeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment
Jul 8, 2024
07:54 AM EDT, 07/08/2024 (MT Newswires) -- iTeos Therapeutics ( ITOS ) said Monday it has dosed the first patient in its phase 3 trial of belrestotug with dostarlimab, triggering a $35 million development milestone payment from its belrestotug partner GSK (GSK). The global, randomized, double-blind trial aims to compare the efficacy of belrestotug with dostarlimab against a placebo combined...
Market Chatter: KKR Reportedly Looking to Revive Sale of Goodpack
Market Chatter: KKR Reportedly Looking to Revive Sale of Goodpack
Jul 8, 2024
07:55 AM EDT, 07/08/2024 (MT Newswires) -- KKR & Co ( KKR ) is considering the revival of the sale of Singapore-based global supply chain and logistics company Goodpack in a potentially multibillion-dollar deal, The Wall Street Journal reported Monday, citing people familiar with the plan. The sources said that the private-equity firm is in early discussions with advisers to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved